Quest Diagnostics(DGX)

Search documents
Quest Diagnostics Releases 2023 Corporate Responsibility Report
Prnewswire· 2024-06-27 10:45
SECAUCUS, N.J., June 27, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today released its 2023 Corporate Responsibility Report. This year's report provides information on the company's corporate responsibility strategy and environmental, social, and governance (ESG) priorities, which align with The Quest Way, the company's approach to achieving its goals. The Quest Way is comprised of the company's Purpose, strategy and culture. Quest Diagnostics Releases 2 ...
Quest Diagnostics to Acquire Select Lab Assets from Allina Health
Prnewswire· 2024-06-26 20:03
SECAUCUS, N.J. and MINNEAPOLIS, June 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and Allina Health, a leading, non-profit health care system, today announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin. "Our transaction with Allina Health will extend access to Quest's e ...
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
ZACKS· 2024-06-21 16:10
Hims & Hers Heath stock has surged 165.9% in the past year. Estimates for the company's earnings have moved upward from 18 cents to 19 cents for 2024 and from 33 cents to 35 cents for 2025 in the past seven days. Additionally, Quest Diagnostics is making headway with several promising opportunities in its robust M&A pipeline, with the recent acquisition of Lenco contributing to its first-quarter growth. Base volume growth within Hospital Lab Services will continue, courtesy of the strength in professional l ...
Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024
Prnewswire· 2024-06-19 19:00
The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call. About Quest Diagnostics Anyone listening to the call is encouraged to read the company's periodic reports on file with the Securities and Exchange Commission, including the discussion o ...
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
ZACKS· 2024-06-18 14:01
Company Overview - Quest Diagnostics has completed the acquisition of PathAI Diagnostics, enhancing its leadership in oncology and subspecialized pathology services [6] - The acquisition aims to accelerate the adoption of AI and digital pathology to improve cancer diagnosis and other diseases [6][20] - The PathAI Diagnostics facility in Memphis has been rebranded as AmeriPath, serving as a national AI and digital R&D center for Quest Diagnostics [13] Industry Insights - The global AI in pathology market was valued at $24 million in 2023 and is projected to grow at a CAGR of 15.6% by 2030 [21] - AI in pathology offers advantages such as improved accuracy, increased efficiency, and enhanced patient care, driven by the demand for better diagnosis and cost control in hospitals [2] - Digital pathology enables the creation of digital images of glass slides, facilitating expert consultations and reducing transportation needs, which addresses workforce shortages in pathology [8] Strategic Collaborations - Quest Diagnostics will license PathAI's AISight digital pathology image management system to enhance its pathology laboratories and customer sites in the U.S. [7] - Both companies may collaborate on developing AI algorithms for research and clinical applications [14] - A research collaboration with Broad Clinical Labs has been announced to demonstrate the clinical value of whole genome sequencing as a first-line genetic test for developmental delay disorders [22] Financial Performance - Quest Diagnostics currently holds a Zacks Rank 3 (Hold) [10] - In the past year, shares of Quest Diagnostics have decreased by 1.2%, while the industry has risen by 15.2% [23]
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
Prnewswire· 2024-05-31 20:08
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in J ...
Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
zacks.com· 2024-05-23 16:36
Quest Diagnostics Q1 Earnings Surpass, Margins Crash Quest Diagnostics Incorporated's first-quarter 2024 adjusted earnings per share of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure. Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter's adjusted figures. GAAP ...
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
Prnewswire· 2024-05-16 20:15
SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Rob CarterRob Carter Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting the technology direction of the F ...
Quest Diagnostics Declares Quarterly Cash Dividend
prnewswire.com· 2024-05-15 21:45
SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. SOURCE Quest Diagnostics About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from ...
Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
Prnewswire· 2024-05-15 12:43
Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional Office-Based Industries SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior y ...